Article
High-resolution mutational profiling suggests the genetic validity of glioblastoma patient-derived pre-clinical models.
PloS one - 1 Jan 2013
Yost Shawn E, Pastorino Sandra, Rozenzhak Sophie, Smith Erin N, Chao Ying S, Jiang Pengfei, Kesari Santosh, Frazer Kelly A, Harismendy Olivier
Abstract excerpt
Recent advances in the ability to efficiently characterize tumor genomes is enabling targeted drug development, which requires rigorous biomarker-based patient selection to increase effectiveness. Consequently, representative DNA biomarkers become equally important in pre-clinical studies. Howeve...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
